Search - tctmd.com

Displaying 361 - 380 of 435

Sort: Relevancy | Date

News Industry News

Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing

August 01, 2017

News Daily News

Delirium’s Dangers Following TAVR: More Evidence

Shelley Wood

July 19, 2017

News Daily News

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Michael O'Riordan

June 26, 2017

News Conference News TVT 2017

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Michael O'Riordan

June 20, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Caitlin E. Cox

May 17, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

REPRISE III: Lotus Valve Matches CoreValve in First Head-to-Head TAVR Trial

News Conference News EuroPCR 2017

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

Shelley Wood

May 16, 2017

News Daily News

Updated PARTNER 2 Valve-in-Valve Registry: More Experience, Better Outcomes

Shelley Wood

May 02, 2017

News Daily News

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

Caitlin E. Cox

April 21, 2017

News Daily News

Permanent Pacemakers After TAVR: Model Helps Predict Individual Patient Risk With Sapien 3

L.A. McKeown

April 12, 2017

Presentation

A Highly Predictive Risk Model for New Permanent Pacemaker Implantation After Sapien 3 TAVR

April 12, 2017

News Conference News ACC 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Shelley Wood

March 24, 2017

News Daily News

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Todd Neale

March 22, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

Advertisement

Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing

Delirium’s Dangers Following TAVR: More Evidence

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

TCTMD’s Top 10 Most Popular Stories for May 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

Updated PARTNER 2 Valve-in-Valve Registry: More Experience, Better Outcomes

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

Permanent Pacemakers After TAVR: Model Helps Predict Individual Patient Risk With Sapien 3

A Highly Predictive Risk Model for New Permanent Pacemaker Implantation After Sapien 3 TAVR

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Live From Washington: ACC 2017, Day Three

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content